Show simple item record

dc.contributor.authorTymms, Kathleen
dc.contributor.authorKelly, Ayano
dc.contributor.authorBird, Paul
dc.contributor.authorGriffiths, Hedley
dc.contributor.authorde Jager, Julien
dc.contributor.authorLittlejohn, Geoff
dc.contributor.authorLouw, Sandra
dc.contributor.authorRoberts, Lynden
dc.contributor.authorYoussef, Peter
dc.contributor.authorZochling, Jane
dc.contributor.authorNichols, Dave
dc.date.accessioned2021-11-08T05:56:30Z
dc.date.available2021-11-08T05:56:30Z
dc.date.issued2018
dc.identifier.issn1756-1841
dc.identifier.doi10.1111/1756-185X.13127
dc.identifier.urihttp://hdl.handle.net/10072/409948
dc.description.abstractAim: To describe the treatment regimens, duration of therapy and reasons for disease-modifying antirheumatic drug (DMARD) cessation in a large psoriatic arthritis (PsA) cohort. Methods: A retrospective non-interventional multi-centre study using Audit4 electronic medical records, with de-identified, routinely collected clinical data from rheumatology practices in the OPAL consortium (Optimising Patient outcomes in Australian rheumatoLogy) during November 2015. Baseline characteristics, type and duration of conventional and biologic DMARDs (cDMARD and bDMARD, respectively), disease activity (Disease Activity Score of 28 joints C-reactive protein [DAS28-CRP]), and reasons for treatment cessation were recorded. Results: A total of 3422 rheumatologist-diagnosed PsA patients were included: 60% female, mean age 54 years and disease duration 10 years. Of patients with treatment recorded (n = 2948), 46% were on cDMARD monotherapy, 19% bDMARD monotherapy, 13% combination bDMARD and cDMARDs, 11% combination cDMARDs and 10% no DMARDs. Of those with DAS28-CRP results (n = 494), the highest mean DAS28-CRP was 3.32 on combination cDMARDs, and the lowest was 2.19 on bDMARD monotherapy. Median duration on cDMARD monotherapy was 33.5 months (n = 2232), on bDMARD monotherapy 110.1 months (n = 751), on combination bDMARD and cDMARDs 68.5 months (n = 559). The most common reasons for cessation of cDMARD monotherapy was adverse reactions (41%), for bDMARD monotherapy lack of efficacy (26%), and for combination bDMARD and cDMARDs treatment completed or no longer required (37%). Conclusion: Most PsA patients were prescribed DMARD therapies with a large proportion receiving cDMARDs. Patients on combination cDMARD therapies had the highest DAS28-CRP results. Adverse reactions were the most common reason for cessation of cDMARD monotherapy, whereas for bDMARD monotherapy it was lack of efficacy.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherJohn Wiley and Sons
dc.relation.ispartofpagefrom510
dc.relation.ispartofpageto516
dc.relation.ispartofissue2
dc.relation.ispartofjournalInternational Journal of Rheumatic Diseases
dc.relation.ispartofvolume21
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchImmunology
dc.subject.fieldofresearchMedical microbiology
dc.subject.fieldofresearchcode3202
dc.subject.fieldofresearchcode3204
dc.subject.fieldofresearchcode3207
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsRheumatology
dc.subject.keywordsclinical aspects
dc.subject.keywordsdrug treatment
dc.titlePsoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: A multi-centre Australian study
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationTymms, K; Kelly, A; Bird, P; Griffiths, H; De Jager, J; Littlejohn, G; Louw, S; Roberts, L; Youssef, P; Zochling, J; Nichols, D, Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: A multi-centre Australian study, International Journal of Rheumatic Diseases, 2018, 21 (2), pp. 510-516
dc.date.updated2021-11-08T05:52:33Z
gro.hasfulltextNo Full Text
gro.griffith.authorde Jager, Julien P.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record